DUBLIN, December 02, 2021--(BUSINESS WIRE)--The "Global Human Microbiome Therapeutics Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
The human microbiome therapeutics market is poised to grow by $516.08 mn during 2021-2025, progressing at a CAGR of 47.79%
This study identifies the side effects of existing treatment as one of the prime reasons driving the human microbiome therapeutics market growth during the next few years. The market is driven by the growing prevalence of chronic diseases and robust pipeline.
The report on the human microbiome therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The human microbiome therapeutics market analysis includes the application segment and geographic landscape.
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human microbiome therapeutics market vendors that include 4D pharma Plc, ENTEROME SA, Ferring B.V., Johnson and Johnson Inc., Kaleido Biosciences Inc., OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd.
Also, the human microbiome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Key Topics Covered:
Value chain analysis
Market segment analysis
Market size 2020
Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market Segmentation by Application
Comparison by Application
Gastrointestinal disorders - Market size and forecast 2020-2025
Infectious diseases - Market size and forecast 2020-2025
Others - Market size and forecast 2020-2025
Market opportunity by Application
North America - Market size and forecast 2020-2025
Europe - Market size and forecast 2020-2025
Asia - Market size and forecast 2020-2025
ROW - Market size and forecast 2020-2025
Key leading countries
Market opportunity By Geographical Landscape
Market positioning of vendors
4D pharma Plc
Johnson and Johnson Inc.
Kaleido Biosciences Inc.
OptiBiotix Health Plc
PureTech Health Plc
Second Genome Therapeutics
Seres Therapeutics Inc.
Takeda Pharmaceutical Co. Ltd
For more information about this report visit https://www.researchandmarkets.com/r/sgwttp
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005711/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900